Build vs. Buy a Telehealth Platform: How to Decide

Buy if your needs look like everyone else's: video visits, scheduling, standard billing. Build when your workflow, your data, or your regulatory position is what makes your product different. For most teams the honest answer is a hybrid: buy the commodity parts and build the part that sets you apart.

Side by side

Buy when...

• Video visits are a step in your service, not the service itself.
• Speed matters more than control (a pilot, a first clinic, a funding deadline).
• A standard workflow fits your care model.

Build when...

• The way you deliver care is your edge, and no product supports it.
• You need to own the data, the audit trail, or the infrastructure.
• Per-seat pricing would punish you as you grow.

Five questions that settle it

1. Is the visit your product, or just a step? If it's a step, buy.
2. Who has to own the data? If it must be you, check the vendor's export and exit terms before you sign.
3. How unusual is your workflow? Specialty care, multiple languages, or patient groups with special needs often outgrow off-the-shelf tools.
4. Which rules touch you? Any vendor that handles patient data needs a signed business associate agreement. And if your platform diagnoses or triages with AI, it may count as a medical device. Our guide to SaMD vs. non-regulated software shows how to tell.
5. What happens at ten times your size? Price the next three years, not the first month.

What changed recently (and why it matters for the choice)

• Medicare: Congress extended the Medicare telehealth flexibilities through December 31, 2027, in the funding law signed on February 3, 2026. They're still temporary, so billing rules could change again.
• Controlled substances: DEA's flexibilities for prescribing by telemedicine without an in-person visit run through December 31, 2026. In late August 2026 DEA sent its final "special registration" rule for White House review. The proposed rule includes a registration category for platforms involved in prescribing controlled substances.
• What to do with that: pick an architecture whose rules you can configure, not hardcode. Platforms that treat regulation as a setting survive the changes. Platforms that bake it in get rebuilt.

Two examples from our work

• Hand to Hold moved from a white-label community app to a custom build, once the template platform couldn't support their workflows and the subscription costs kept growing. They report 90% lower maintenance costs and full ownership of their data. It isn't a video-visit product, but it's the same trade-off.
• MedCycle Network started with a fast AI-built prototype, then needed a custom backend for audit logs and data ownership. That's the hybrid path: prototype first, own the foundation next.

How to decide, in four steps

1. List your must-haves and the three things you'd never compromise on.
2. Price the next three years of each option, including per-seat fees and integration work.
3. Test the exit: can you export your data and keep your patient accounts if you leave?
4. Pilot before you commit, with real clinicians and real patients.

Not sure which way you lean? See how we build telemedicine platforms or talk to us. We'll tell you honestly if buying is the better call.

Last reviewed: October 2026. This is general information, not legal or regulatory advice.